Baricitinib for COVID-19: a suitable treatment? - Authors' reply

doi:10.1016/S1473-3099(20)30270-X

Comment

. 2020 Sep;20(9):1013-1014.

doi: 10.1016/S1473-3099(20)30270-X. Epub 2020 Apr 3.

Baricitinib for COVID-19: a suitable treatment? - Authors' reply

Peter J Richardson¹, Mario Corbellino², Justin Stebbing³

Affiliations

¹ Benevolent AI, London, UK.
² III Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy.
³ Department of Surgery and Cancer, Imperial College, London W12 0NN, UK. Electronic address: j.stebbing@imperial.ac.uk.

PMID: 32251639
PMCID: PMC7271155
DOI: 10.1016/S1473-3099(20)30270-X

Comment

Baricitinib for COVID-19: a suitable treatment? - Authors' reply

Peter J Richardson et al. Lancet Infect Dis. 2020 Sep.

. 2020 Sep;20(9):1013-1014.

doi: 10.1016/S1473-3099(20)30270-X. Epub 2020 Apr 3.

Authors

Peter J Richardson¹, Mario Corbellino², Justin Stebbing³

Affiliations

¹ Benevolent AI, London, UK.
² III Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy.
³ Department of Surgery and Cancer, Imperial College, London W12 0NN, UK. Electronic address: j.stebbing@imperial.ac.uk.

PMID: 32251639
PMCID: PMC7271155
DOI: 10.1016/S1473-3099(20)30270-X

No abstract available

PubMed Disclaimer

Comment on

COVID-19: combining antiviral and anti-inflammatory treatments.
Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. Stebbing J, et al. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27. Lancet Infect Dis. 2020. PMID: 32113509 Free PMC article. No abstract available.
Baricitinib for COVID-19: a suitable treatment?
Favalli EG, Biggioggero M, Maioli G, Caporali R. Favalli EG, et al. Lancet Infect Dis. 2020 Sep;20(9):1012-1013. doi: 10.1016/S1473-3099(20)30262-0. Epub 2020 Apr 3. Lancet Infect Dis. 2020. PMID: 32251638 Free PMC article. No abstract available.

Cited by

The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.
Choudhary S, Sharma K, Silakari O. Choudhary S, et al. Microb Pathog. 2021 Jan;150:104673. doi: 10.1016/j.micpath.2020.104673. Epub 2020 Dec 2. Microb Pathog. 2021. PMID: 33278517 Free PMC article. Review.
Application of Artificial Intelligence in COVID-19 drug repurposing.
Mohanty S, Harun Ai Rashid M, Mridul M, Mohanty C, Swayamsiddha S. Mohanty S, et al. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1027-1031. doi: 10.1016/j.dsx.2020.06.068. Epub 2020 Jul 3. Diabetes Metab Syndr. 2020. PMID: 32634717 Free PMC article. Review.
Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19.
Massalska M, Maslinski W, Ciechomska M. Massalska M, et al. Cells. 2020 Aug 11;9(8):1876. doi: 10.3390/cells9081876. Cells. 2020. PMID: 32796683 Free PMC article. Review.
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.
Kumar S, Basu M, Ghosh P, Pal U, Ghosh MK. Kumar S, et al. Genes Dis. 2023 Jul;10(4):1402-1428. doi: 10.1016/j.gendis.2022.12.019. Epub 2023 Apr 7. Genes Dis. 2023. PMID: 37334160 Free PMC article. Review.
Experimental Pharmacotherapy for COVID-19: The Latest Advances.
Pagliano P, Scarpati G, Sellitto C, Conti V, Spera AM, Ascione T, Piazza O, Filippelli A. Pagliano P, et al. J Exp Pharmacol. 2021 Jan 7;13:1-13. doi: 10.2147/JEP.S255209. eCollection 2021. J Exp Pharmacol. 2021. PMID: 33442304 Free PMC article. Review.

See all "Cited by" articles

References

1. Richardson P, Griffin I, Tucker C. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31. - PMC - PubMed
1. Stebbing J, Phelan A, Griffin I. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–402. - PMC - PubMed
1. Cameron MJ, Ran L, Xu L. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007;81:8692–8706. - PMC - PubMed
1. Channappanavar R, Fehr AR, Zheng J. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;130:3625–3639. - PMC - PubMed
1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Richardson P, Griffin I, Tucker C. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31. - PMC - PubMed

[2] Richardson P, Griffin I, Tucker C. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31. - PMC - PubMed

[3] Stebbing J, Phelan A, Griffin I. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–402. - PMC - PubMed

[4] Stebbing J, Phelan A, Griffin I. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–402. - PMC - PubMed

[5] Cameron MJ, Ran L, Xu L. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007;81:8692–8706. - PMC - PubMed

[6] Cameron MJ, Ran L, Xu L. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007;81:8692–8706. - PMC - PubMed

[7] Channappanavar R, Fehr AR, Zheng J. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;130:3625–3639. - PMC - PubMed

[8] Channappanavar R, Fehr AR, Zheng J. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;130:3625–3639. - PMC - PubMed

[9] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. - PMC - PubMed

[10] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Baricitinib for COVID-19: a suitable treatment? - Authors' reply

Affiliations

Baricitinib for COVID-19: a suitable treatment? - Authors' reply

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources